Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytovant Sciences

Division of Roivant Sciences Inc.
www.cytovant.com

Latest From Cytovant Sciences

Start-Up Quarterly Statistics: Financings Surged In Q4 While M&A Waned

A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.

Deals Financing

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Roivant Asia Cell Therapy Holdings Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Hong Kong
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Roivant Sciences Inc.
  • Senior Management
  • John Xu, PhD, Pres.
  • Contact Info
  • Cytovant Sciences
    ,
    Hong Kong
UsernamePublicRestriction

Register